Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
80% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PBYI: No Debt )
PBYI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
73% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
PBYI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 200.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -80.47
PBYI's ROE (%) is ranked higher than
61% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. PBYI: -80.47 )
PBYI' s 10-Year ROE (%) Range
Min: -81.13   Max: -37.64
Current: -80.47

-81.13
-37.64
ROA (%) -68.35
PBYI's ROA (%) is ranked higher than
59% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. PBYI: -68.35 )
PBYI' s 10-Year ROA (%) Range
Min: -1700   Max: -36.94
Current: -68.35

-1700
-36.94
ROC (Joel Greenblatt) (%) -6201.50
PBYI's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. PBYI: -6201.50 )
PBYI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6890.33   Max: -2978.59
Current: -6201.5

-6890.33
-2978.59
EPS Growth (%) 883.00
PBYI's EPS Growth (%) is ranked higher than
100% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. PBYI: 883.00 )
PBYI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 883
Current: 883

0
883
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PBYI Guru Trades in Q4 2013

Steven Cohen 5,800 sh (-63.29%)
» More
Q1 2014

PBYI Guru Trades in Q1 2014

Jim Simons 12,600 sh (New)
Pioneer Investments 30,901 sh (New)
Steven Cohen 78,938 sh (+1261%)
» More
Q2 2014

PBYI Guru Trades in Q2 2014

Steven Cohen 327,900 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
» More
Q3 2014

PBYI Guru Trades in Q3 2014

Jim Simons 30,200 sh (New)
RS Investment Management 92,188 sh (New)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 48.80
PBYI's P/B is ranked higher than
58% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. PBYI: 48.80 )
PBYI' s 10-Year P/B Range
Min: 0   Max: 51.1
Current: 48.8

0
51.1
EV-to-EBIT -120.82
PBYI's EV-to-EBIT is ranked lower than
53% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PBYI: -120.82 )
PBYI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -120.82

Current Ratio 5.45
PBYI's Current Ratio is ranked higher than
76% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PBYI: 5.45 )
PBYI' s 10-Year Current Ratio Range
Min: 0.67   Max: 91.58
Current: 5.45

0.67
91.58
Quick Ratio 5.45
PBYI's Quick Ratio is ranked higher than
77% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. PBYI: 5.45 )
PBYI' s 10-Year Quick Ratio Range
Min: 0.67   Max: 91.58
Current: 5.45

0.67
91.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 55.90
PBYI's Price/Net Cash is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. PBYI: 55.90 )
PBYI' s 10-Year Price/Net Cash Range
Min: 4.69   Max: 58.19
Current: 55.9

4.69
58.19
Price/Net Current Asset Value 55.36
PBYI's Price/Net Current Asset Value is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. PBYI: 55.36 )
PBYI' s 10-Year Price/Net Current Asset Value Range
Min: 4.39   Max: 57.63
Current: 55.36

4.39
57.63
Price/Tangible Book 48.76
PBYI's Price/Tangible Book is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. PBYI: 48.76 )
PBYI' s 10-Year Price/Tangible Book Range
Min: 4.18   Max: 50.76
Current: 48.76

4.18
50.76
Earnings Yield (Greenblatt) -0.80
PBYI's Earnings Yield (Greenblatt) is ranked higher than
83% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. PBYI: -0.80 )
PBYI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.4   Max: 0
Current: -0.8

-1.4
0
Forward Rate of Return (Yacktman) -0.32
PBYI's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. PBYI: -0.32 )
PBYI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -0.32

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany
Puma Biotechnology Inc, a Delaware corporation was incorporated on April 27, 2007. The Company is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of advanced breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of advanced cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive worldwide rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company has modified Pfizer's clinical development strategy and during the next 12 to 18 months plan to: commence Phase III clinical trials evaluating the use of with HER2-positive metastatic breast cancer who have previously failed two or more prior treatment; continue the ongoing Phase II clinical trial of neratinib in the neoadjuvant treatment of HER2 positive breast cancer, in patients with HER2 positive metastatic breast cancer that has metastasized to the brain; and continue to evaluate the application of neratinib in the treatment of other forms of HER2 positive cancers where there may be unmet medical needs. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 20 2014
PUMA BIOTECHNOLOGY, INC. Financials Nov 18 2014
Puma Biotechnology Falls on Disappointing Neratinib Data Nov 17 2014
Puma Biotechnology Slumps: PBYI Tumbles 9.7% in Session Nov 17 2014
All in all, another solid week for U.S. equities... Nov 14 2014
Midday movers: FibroGen, Google, McDonald's & more Nov 14 2014
Puma Biotech says cancer drug fails mid-stage study Nov 13 2014
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 13 2014
Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive... Nov 13 2014
Puma Biotechnology to Present at Stifel 2014 Healthcare Conference Nov 12 2014
Puma Biotechnology to Present at Stifel 2014 Healthcare Conference Nov 12 2014
Puma Biotech beats 3Q profit forecasts Nov 10 2014
Puma Biotech beats 3Q profit forecasts Nov 10 2014
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
Puma Biotechnology Reports Third Quarter 2014 Financial Results Nov 10 2014
PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
Intercept Seen as Poster-boy for Possible Biotech Bubble Nov 10 2014
Will Puma Biotechnology (PBYI) Disappoint this Earnings? Nov 10 2014
Auerbach, Yancopoulos To Speak At Forbes Healthcare Summit Nov 03 2014
Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore! Oct 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK